Pharmaceutical combination comprising an ibat inhibitor and a bile acid binder

A method for treating a liver disease selected from the group consisting of primary biliary cirrhosis (PBC);

• Alagille syndrome (ALGS);
• primary sclerosing cholangitis (PSC);
• and progressive familial intrahepatic cholestasis (PFIC), the method comprising orally administering to a subject in need of such treatment a therapeutically effective amount of (4R,5R)-1-((4-(4-(3,3-dibutyl-7-(dimethylamino)-2,3,4,5-tetrahydro-4-hydroxy-1,1-dioxido-1-benzothiepin-5-yl)phenoxy)methyl)phenyl)methyl-4-aza-1-azoniabicyclo[2.2.2]octane chloride.

A method for treating a liver disease selected from the group consisting of primary biliary cirrhosis (PBC);

• Alagille syndrome (ALGS);
• primary sclerosing cholangitis (PSC);
• and progressive familial intrahepatic cholestasis (PFIC), the method comprising orally administering to a subject in need of such treatment a therapeutically effective amount of 1-[4-[4-[(4R,5R)-3,3-dibutyl-7-(dimethylamino)-2,3,4,5-tetrahydro-4-hydroxy-1,1-dioxido-1-benzothiepin-5-yl]phenoxy]butyl]4-aza-1-azoniabicyclo[2.2.2]octane methane sulfonate.

A method for treating primary biliary cirrhosis (PBC) comprising orally administering to a subject in need of such treatment a therapeutically effective amount of (4R,5R)-1-((4-(4-(3,3-dibutyl-7-(dimethylamino)-2,3,4,5-tetrahydro-4-hydroxy-1,1-dioxido-1-benzothiepin-5-yl)phenoxy)methyl)phenyl)methyl-4-aza-1-azoniabicyclo[2.2.2]octane chloride;

• and a cholesterol absorption antagonist, or a pharmaceutically acceptable salt thereof.